Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 116-120

  Di Maio, Massimo ^a   Krzakowski, Maciej ^b   Fougeray, Ronan ^c   Kowalski, Dariusz M ^b   Gridelli, Cesare ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d S G MOSCATI HOSPITAL   (Italy)

Author keywords

Advanced NSCLC; Docetaxel; Performance status; Prognostic score; Response to first line; Second line treatment; Validation; Vinflunine

Indexed keywords

DOCETAXEL; VINFLUNINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DECISION MAKING; DRUG EFFECT; DRUG EFFICACY; EXTERNAL VALIDITY; FEMALE; HUMAN; LIFE EXPECTANCY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84861737552     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.013     Document Type: Article

References (13)

1. Gridelli C., Ardizzoni A., Ciardiello F., Hanna N., Heymach J.V., Perrone F., et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:430-440.
2. Di Maio M., Lama N., Morabito A., Smit E.F., Georgoulias V., Takeda K., et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010, 46:735-743.
3. Krzakowski M., Ramlau R., Jassem J., Szczesna A., Zatloukal P., Von Pawel J., et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 2010, 28:2167-2173.
4. Kaplan E.L., Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-481.
5. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
6. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
7. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
8. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
9. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70. ESMO Guidelines Working Group.
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase III trial. Lancet 2008, 372:1809-1818.
12. Weiss G.J., Rosell R., Fossella F., Perry M., Stahel R., Barata F., et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18:453-460.
13. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.